Genmab says Rina-S showed durable responses in ovarian cancer

• Confirmed objective response rate was 45.9% in 109 treated patients.
• Median duration of response was 12.1 months.
• Median progression-free survival was 9.5 months.
• No safety signals were observed for ocular toxicity, peripheral neuropathy, interstitial lung disease or stomatitis.

Genmab on October 3 said its Rina-S antibody-drug conjugate delivered durable responses in patients with platinum-resistant ovarian cancer. The data came from Part C of the Phase 1/2 RAINFOL-01 trial and were presented in Montreal at the IGCS Congress 2026.

Genmab says Rina-S showed durable responses in ovarian cancer

Response data

Among 109 treated patients, Rina-S produced a confirmed objective response rate of 45.9%, with five complete responses. Genmab said the median duration of response was 12.1 months, and 51% of responders were still in response at one year.

The company also reported a median progression-free survival of 9.5 months. It said antitumor activity was seen regardless of FRα expression levels, including low expression and non-expressors, and regardless of prior treatment with mirvetuximab.

Study population

The Part C cohort tested Rina-S 120 mg/m² every three weeks as monotherapy in patients with platinum-resistant high-grade serous ovarian, primary peritoneal or fallopian tube cancer. Eligible patients had received one to three prior lines of therapy, while those whose last prior therapy was mirvetuximab could have received up to four.

More than half the patients, or 53%, had received three or four prior lines of therapy. All had received prior bevacizumab and taxane therapy. Genmab said 49.5% had received a prior PARP inhibitor and 33% had received prior mirvetuximab soravtansine.

Safety

The most common treatment-emergent adverse events were fatigue, nausea, vomiting, constipation, decreased appetite and abdominal pain. Hematologic events included anemia, neutropenia, decreased platelet count and thrombocytopenia.

Serious adverse events were reported in approximately one-third of participants. Treatment discontinuation because of treatment-emergent adverse events occurred in 5.5% of participants. Genmab said no safety signals were seen for ocular toxicity, peripheral neuropathy, interstitial lung disease or stomatitis.

Development program

Genmab said Rina-S is being evaluated across multiple gynecologic cancers and other solid tumors. Its program includes four Phase 3 trials in platinum-resistant ovarian cancer, recurrent or progressive endometrial cancer, platinum-sensitive ovarian cancer maintenance therapy and second-line platinum-sensitive ovarian cancer.

Additional studies include the Phase 1/2 RAINFOL-01 trial and Phase 2 trials in non-small cell lung cancer and advanced gastrointestinal cancers.

The safety and efficacy of Rina-S have not been established.